An injection pen of Zepbound, Eli Lilly’s weight-loss drug, is displayed in New York City, December 11, 2023. [Photo: Brendan ...

Vice President Kamala Harris on the campaign trail has frequently touted capping the price of insulin at $35 a month as a ...

Eli Lilly's stock valuation sank by $100 billion Wednesday morning after the pharma giant reported third quarter earnings.

Nearly one-third of those patients were paying $35 or far more per month in 2019, according to the latest available data from ...

Eli Lilly is set to report Q3 earnings Wednesday, as the pharma giant continues to gain market share in the weight loss drug ...

The global injection pen market is expanding at a fast rate with the growing prevalence of chronic diseases, and increasing demand for convenient self-administration options. This trend is a move ...

The global injection pen market is poised for significant growth, with projections indicating a robust compound annual growth rate (CAGR) of 7.0% from 2022 to 2033. The market is expected to escalate ...

The insulin is facing supply shortages as diabetes patients increasingly turn to GLP-1 weight loss drugs such as Ozempic and ...

The global insulin pens market is witnessing unprecedented growth, propelled by the escalating prevalence of diabetes worldwide. According to recent industry reports, the market, valued at USD 35 ...

Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and ...

Shares of Eli Lilly have gained considerably throughout 2024, thanks in large part to the company's success in diabetes and obesity care. Outside of weight loss, Eli Lilly has a major opportunity ...